Cardioprotective effect of 2,3-dehydrosilybin preconditioning in isolated rat heart

2,3-dehydrosilybin (DHS) is a minor component of silymarin, Silybum marianum seed extract, used in some dietary supplements. One of the most promising activities of this compound is its anticancer and cardioprotective activity that results, at least partially, from its cytoprotective, antioxidant, a...

Full description

Saved in:
Bibliographic Details
Published in:Fitoterapia 2019-01, Vol.132, p.12-21
Main Authors: Gabrielová, Eva, Bartošíková, Lenka, Nečas, Jiří, Modrianský, Martin
Format: Article
Language:English
Subjects:
Anticancer properties
Antioxidants
Coronary artery
Dehydrosilybin
Diet
Dietary supplements
Heart
Infarction
Ischemia
Ischemia-reperfusion injury
Kinases
Myocardial ischemia
Occlusion
Perfusion
Preconditioning
Proteins
Reperfusion
Rodents
Signalosomes
Silymarin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:2,3-dehydrosilybin (DHS) is a minor component of silymarin, Silybum marianum seed extract, used in some dietary supplements. One of the most promising activities of this compound is its anticancer and cardioprotective activity that results, at least partially, from its cytoprotective, antioxidant, and chemopreventive properties. The present study investigated the cardioprotective effects of DHS in myocardial ischemia and reperfusion injury in rats. Isolated hearts were perfused by the Langendorff technique with low dose DHS (100 nM) prior to 30 min of ischemia induced by coronary artery occlusion. After 60 min of coronary reperfusion infarct size was determined by triphenyltetrazolium staining, while lactatedehydrogenase activity was evaluated in perfusate samples collected at several timepoints during the entire perfusion procedure. Signalosomes were isolated from a heart tissue after reperfusion and involved signalling proteins were detected. DHS reduced the extent of infarction compared with untreated control hearts at low concentration; infarct size as proportion of ischemic risk zone was 7.47 ± 3.1% for DHS versus 75.3 ± 4.8% for ischemia. This protective effect was comparable to infarct limitation induced by ischemic preconditioning (22.3 ± 4.5%). Selective inhibition of Src-family kinases with PP2 (4-Amino-3-(4-chlorophenyl)-1-(t-butyl)-1H-pyrazolo[3,4-d]pyrimidine) abrogated the protection afforded by DHS. This study provides experimental evidence that DHS can mediate Src-kinase-dependent cardioprotection against myocardial damage produced by ischemia/reperfusion injury. [Display omitted]
ISSN:0367-326X
1873-6971
DOI:10.1016/j.fitote.2018.10.028